electroCore Submits 510(k) Premarket Notification to FDA for Quell Platform

Article summary

electroCore, Inc. has submitted a 510(k) premarket notification to the FDA seeking clearance for its Quell wearable neuromodulation platform to treat chronic chemotherapy-induced peripheral neuropathy.